Orum Therapeutics

Sentiment around initial public offerings (IPOs) appears to be slowly recovering in South Korea as the market stabilizes somewhat amid ongoing political uncertainties at home and abroad. A couple of b

2024 was an eventful year for the South Korean biopharma industry with the emergence of several key themes that look set to carry over into the new year. The sector is facing a new growth chapter fuel

A series of initial public offering plans unveiled by South Korean biopharma firms, notably Orum Therapeutics Inc., is raising hopes of a recovery in the general funding situation in the sector. After

Signs of broader recovery are emerging in the South Korean biotech sector following the landmark US approval of Yuhan Corporation 's novel lung cancer drug Lazcluze (lazertinib) in August through lic